Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

February 28, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

November 30, 2015

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

Cervarix™

2 doses intramuscularly in the deltoid muscle of the non-dominant arm

BIOLOGICAL

Havrix

2 doses intramuscularly in the deltoid muscle of the dominant arm